Although IL-2 treatment can increase the apoptotic rate of HepG2 cells, it also upregulates the expression of TAZ, a pro-tumorigenic signal in several cancers including pancreatic cancer [65], colorectal cancer [66], gastric cancer [67] and breast cancer [68]. This evidence concerns the gene IL2 and familial pancreatic carcinoma.